中新网丽水12月30日电(傅飞扬)12月30日，浙江清华长三角研究院丽水通济实验室正式启用，标志着丽 水市莲都区在建设高能级科创平台方面取得了新的突破——该实验室将聚焦美丽健康等领域，重点围绕 产业分析、技术研发、成果转化与双招双引四个方面系统发力，有力推动当地美丽健康产业提质增效。 作为长三角地区唯一水和空气质量均进入全国前十的生态高地，莲都既有"天生丽质"的生态环境，更有 把生态优势转化为产业优势、培育经济新增长点的迫切需要。 积极打造丽水首个浙江省医药创新和审评柔性服务站，企业可就近享受基本业务咨询、审评资料预审等 全链条服务；设立美丽健康产业服务中心，为企业提供"一企一员、一企一档、一企一案"全流程专业服 务；出台三项赋能产业发展的政策大礼包，成立省市区三级联动基金合作平台，推动总投资150亿元的 39个重大项目集中签约…… 为聚力打造百亿级美丽健康产业链，近年来，该区将美丽健康产业作为支柱产业，紧扣生态美妆、时尚 医美、口腔医疗、现代中药、健康茶咖、宠物产品六大主赛道，绘制了清晰的产业路线图。 在碧湖平原，总投资33亿元的"生态纳爱斯智能工厂和产业核心区项目"正加速推进。 "我们依托莲都乃至丽水丰富 ...

近日，河南省"豫你携手 创赢未来"青年科技人才创新创业大赛圆满落幕，来自河南省淅川县的大丹江 科技股份有限公司凭借"汽车底盘磁流变工作缸的研发及产业化"项目，从近2000个参赛项目、8500余名 参赛者中脱颖而出，成功斩获铜奖殊荣。 大丹江公司此次获奖的磁流变工作缸项目，核心依托磁流变液智能减振技术，可实现毫秒级阻尼力调 节，兼具响应快、功耗低、可靠性强等优势，能大幅提升汽车驾乘舒适性与操控性，在汽车工业领域具 有广阔产业化前景。该项目的成功突围，既是对企业技术创新实力的权威认可，更是淅川县培育优质创 新主体、推动产业转型升级的生动实践。 同时，坚持创优环境，为企业发展增添新动能。多渠道融资，有效盘活闲置土地，规划建设了汽配、乡 村振兴、移民、淅减四大产业园，建成了福森新能源10GWh储能电池、晶多多人工晶体新材料、南阳 美航汽车零部件等共计39万平方米的标准化厂房，实现企业"拎包入驻"。制定操作性强的企业梯次培育 计划，落实"项目秘书"及科级干部"双分包"工作机制，切实解决企业水、电、气、能、地等问题，助力 企业扩能增产、提质增效。结合企业需求，联合南阳农职院、南阳信息工程学校等职业院校，定向培育 一批机械 ...

Group 1 - The first Shantou Health Industry Innovation Development Conference and Health Product Expo was held on August 8, 2025, marking an important milestone in the development of the health industry in Shantou with the theme "Healthy China, Vibrant Shantou" [1] - The conference attracted over 300 enterprises, showcasing a comprehensive view of the industry including traditional and modern medicine, health food, and medical aesthetics. It featured AI medical services and free health consultations for the public [3] - The event announced 10 measures to promote the health industry, established strategic cooperation with 7 international chambers of commerce, signed 13 projects, and initiated 12 key projects [3] Group 2 - The health industry is a powerful engine for high-quality development, deeply rooted in Shantou's history, with significant contributions from local enterprises and charitable organizations since the Song and Yuan dynasties [6] - Shantou currently has 165 "Four Up" enterprises covering the entire industry chain, with local products dominating over 90% of the national market for certain anti-infection drugs and high-end medical devices exported to over 100 countries [8] - Future plans include the "123 Action Plan" to develop a core hub for the bird's nest industry, attract over 100 health enterprises to establish headquarters and production bases, and create a competitive trillion-level industry cluster [10]

Core Insights - The Xichuan Advanced Manufacturing Development Zone has been recognized as a digital transformation promotion center in Henan Province due to its solid digital infrastructure and innovative transformation practices [1] Group 1: Digital Transformation and Industry Focus - The development zone covers an area of 13.03 square kilometers and hosts 184 enterprises, focusing on digital transformation in four major industry clusters: automotive parts, modern traditional Chinese medicine, new energy, and new materials [1] - The automotive parts industry, led by Xijian, includes 86 associated enterprises with a market share of 20%, primarily producing shock absorbers and various components [2] - The modern traditional Chinese medicine industry, led by Fusen Pharmaceutical, comprises 35 associated enterprises, with market shares of 35.5% for oral solutions and 91.6% for injection solutions of the same product [2] Group 2: Innovation and Support Policies - The development zone has implemented policies to support technological innovation, allocating 50 million yuan in special funds for enterprises, with the automotive parts sector receiving 60 million yuan in provincial R&D support [3] - The area has established a national-level enterprise technology center, three nationally recognized laboratories, and numerous provincial-level centers, with 38 high-tech enterprises and 21 specialized enterprises [3] Group 3: Infrastructure and Investment - The development zone employs a "management committee + company" model for financing and has developed industrial parks for automotive parts, rural revitalization, and immigration, with 390,000 square meters of standardized factories built [4] - In 2024, the 86 large-scale industrial enterprises in the development zone are projected to achieve a total output value of 7.2 billion yuan, accounting for 90% of the county's industrial output, with an industrial added value of 1.83 billion yuan [4]

Core Viewpoint - Sichuan Province has introduced measures to promote the development of the pharmaceutical and health industry, focusing on six specific sectors: nuclear medicine, biomedicine, medical devices, sports, modern traditional Chinese medicine, and medical beauty [1][2] Group 1: Support for Innovation and Research - The measures support the establishment of national-level research platforms, including key laboratories for biotherapy and oral disease prevention, as well as major scientific infrastructure for translational medicine [1] - Emphasis is placed on collaboration between academic and research institutions and quality enterprises in the industry chain, particularly in areas like malignant tumors and emerging infectious diseases [1] - The initiative aims to develop innovative drug projects in fields such as cell therapy, gene therapy, synthetic biology, and brain science, along with a focus on creating a key research and development catalog for innovative drugs [1] Group 2: Financial Support and Incentives - The measures integrate resources to provide financial support for key industry projects, including a program that offers up to 40% of the total contract amount for project funding, with a maximum of 20 million yuan per project [2] - Specific subsidies are outlined for nuclear medicine projects, with a maximum subsidy of 20% of the project investment and a cap of 2 million yuan, while research projects can receive up to 30% of their R&D investment, capped at 1 million yuan [2] - Additional financial incentives include 40 million yuan annually for the top five cities in sports industry development, and up to 200,000 yuan for outdoor sports base construction projects [2] Group 3: Streamlined Processes - The measures establish a "key project service team" for pharmaceuticals and medical devices, ensuring that innovative drugs complete network review within 15 working days [2]

Company Overview - Changchun High-Tech Industry (Group) Co., Ltd. is a publicly listed company established in accordance with the Company Law and Securities Law of the People's Republic of China [2][3] - The company was approved for its initial public offering of 19 million shares in December 1996 and is listed on the Shenzhen Stock Exchange [2][3] Corporate Structure - The registered capital of the company is RMB 407,937,529 [3] - The company is structured as a long-term existing joint-stock company with a legal representative being the chairman [3][4] - The company has established a Party Committee and a Disciplinary Inspection Committee to ensure political leadership and compliance with regulations [5][6] Governance and Responsibilities - The company’s governance structure includes a board of directors, supervisory board, and senior management, with specific roles and responsibilities outlined in the articles of association [4][6] - The Party Committee is responsible for political construction, ensuring alignment with the central government's policies, and overseeing major company decisions [6][9] - The Disciplinary Inspection Committee is tasked with maintaining party discipline and overseeing anti-corruption efforts within the company [7][8] Business Objectives and Scope - The company aims to develop a diversified business model focusing on biopharmaceuticals and related industries, with real estate as a supplementary sector [11] - The operational scope includes the development, production, and sales of high-tech products, new drug development, and various consulting services [11] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and participation in company decisions, with obligations to comply with laws and regulations [17][18] - The company maintains a shareholder registry to ensure transparency and accountability in shareholder rights [17] Share Issuance and Capital Management - The company has a total of 68.64 million ordinary shares, with specific ownership distribution among founders, public investors, and employees [13][30] - The company can increase capital through various methods, including issuing new shares and distributing stock dividends, subject to shareholder approval [33][34] Meeting Regulations - The company holds annual and extraordinary shareholder meetings, with specific procedures for notification, proposal submission, and voting [56][60] - Shareholder meetings are conducted in compliance with legal requirements, ensuring all shareholders can participate and voice their opinions [60][61]